New Tri-Specific antibody takes on Hard-to-Treat myeloma
NCT ID NCT06375044
First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, then test that dose more closely, while monitoring side effects and any tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SIM0500 (a tri-specific antibody targeting GPRC5D, BCMA, and CD3 proteins)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is an early Phase 1 trial with only 130 participants, so safety and effectiveness are not yet proven. Side effects from the immune system activation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beijing Chaoyang Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
-
Dana Farber Cancer institution
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
-
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute
RECRUITINGNew York, New York, 10029, United States
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300000, China
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic Florida
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
-
The First Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHanzhou, Zhejiang, 310000, China
-
UC Irvine Health
RECRUITINGOrange, California, 92868, United States
-
University of North Carolina Hospitals at Hillsborough
RECRUITINGHillsborough, North Carolina, 27278, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma